Free Newsletter
ALSO NOTED: Korean pharma mired in family feud; Boston Scientific implant gets EU nod;
> Dong-A Pharmaceutical asked Korean authorities to investigate its former chief executive for embezzlement. The nation's top drug maker has been embroiled in a family feud for control for years. Report
> European regulators approved Boston Scientific's new defibrillator known as Confient. Release
> SkyePharma appointed Jeremy Scudamore as non-executive chairman of its board, replacing Jerry Karabelas. Report
> Indian drug maker Cipla and Ugandan partner Quality Chemicals opened a new factory to produce HIV/AIDS meds in the African country. Report
> QLT agreed to take over ForSight Newco, an ocular product company, for $42 million; the deal includes a novel drug-delivery system using "punctal plugs" for a variety of eye conditions. Release
> GlaxoSmithKline is buying into Anacor Pharmaceuticals' research work, inking a deal to in-license boron-containing small molecule anti-infective drug candidates. Report
> Chemistry-related skills are in demand, which is translating to some attractive salaries in the research field. Report
> The Nobel Prize for medicine has gone to three researchers in recognition of their collective work on gene targeting, a process that allows researchers to turn genes off and on in mice. Report
> The market for insomnia drugs in the U.S. is growing at a whopping 29 percent per year, hitting $4.6 billion in 2006 and attracting the attention of a wide range of drug developers. Report
And Finally... Should the FDA allow behind-the-counter drug sales? Poll
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: